Hefei Research Institute has developed a new type of tropomyosin receptor kinase inhibitor

Recently, the research team of Liu Qingsong and Liu Jing, researchers at the Institute of Health and Medical Technology, Hefei Institute of Material Science, Chinese Academy of Sciences, has developed a new small molecule inhibitor of tropomyosin receptor kinase (TRK) IHMT-TRK-284

TRK mainly includes three subtypes of TRKA, TRKB and TRKC, which are respectively encoded by NTRK1, NTRK2 and NTRK3 genes

In the previous study, based on the BaF3 engineered cell bank built by the team, through high-throughput screening, the researchers found that the compound CHFML-ABL-121 has a strong inhibitory effect on TRKA/B/C, but the compound also has a variety of kinases The target has an inhibitory effect, and the drug-making ability is poor

The research was supported by the National Natural Science Foundation of China, the "Individualized Medicine" pilot project of the Chinese Academy of Sciences, and the "Major New Drug Creation" National Science and Technology Special Project

Anti-tumor effect of IHMT-TRK-284 (compd.